NYSE:PFE - Pfizer Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$41.42 +0.26 (+0.63 %)
(As of 08/17/2018 03:43 AM ET)
Previous Close$41.16
Today's Range$41.07 - $41.47
52-Week Range$32.32 - $41.64
Volume15.48 million shs
Average Volume22.34 million shs
Market Capitalization$243.65 billion
P/E Ratio15.63
Dividend Yield3.34%
Beta0.96
Pfizer logoPfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE News and Ratings via Email

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:PFE
CUSIP71708110
Phone212-733-2323

Debt

Debt-to-Equity Ratio0.41
Current Ratio1.16
Quick Ratio0.91

Price-To-Earnings

Trailing P/E Ratio15.63
Forward P/E Ratio13.85
P/E Growth1.98

Sales & Book Value

Annual Sales$52.55 billion
Price / Sales4.69
Cash Flow$3.7965 per share
Price / Cash10.91
Book Value$12.02 per share
Price / Book3.45

Profitability

EPS (Most Recent Fiscal Year)$2.65
Net Income$21.31 billion
Net Margins42.35%
Return on Equity25.35%
Return on Assets10.29%

Miscellaneous

Employees90,200
Outstanding Shares5,952,870,000
Market Cap$243.65 billion

Pfizer (NYSE:PFE) Frequently Asked Questions

What is Pfizer's stock symbol?

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Pfizer declared a quarterly dividend on Thursday, June 28th. Investors of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 annualized dividend and a yield of 3.28%. The ex-dividend date is Thursday, August 2nd. View Pfizer's Dividend History.

How will Pfizer's stock buyback program work?

Pfizer declared that its Board of Directors has authorized a stock buyback program on Tuesday, December 19th 2017, which permits the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company's management believes its shares are undervalued.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) posted its earnings results on Tuesday, July, 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. The biopharmaceutical company had revenue of $13.47 billion for the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The company's revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 EPS. View Pfizer's Earnings History.

When is Pfizer's next earnings date?

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Pfizer.

What guidance has Pfizer issued on next quarter's earnings?

Pfizer issued an update on its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share (EPS) guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.95. The company issued revenue guidance of $53-55 billion, compared to the consensus revenue estimate of $54.25 billion.

What price target have analysts set for PFE?

20 analysts have issued 1 year price targets for Pfizer's shares. Their forecasts range from $37.00 to $45.00. On average, they expect Pfizer's stock price to reach $41.1176 in the next twelve months. This suggests that the stock has a possible downside of 0.7%. View Analyst Price Targets for Pfizer.

What is the consensus analysts' recommendation for Pfizer?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

Are investors shorting Pfizer?

Pfizer saw a increase in short interest in July. As of July 31st, there was short interest totalling 54,661,544 shares, an increase of 5.2% from the July 13th total of 57,638,413 shares. Based on an average trading volume of 20,733,428 shares, the days-to-cover ratio is presently 2.6 days. Approximately 0.9% of the shares of the stock are short sold. View Pfizer's Current Options Chain.

Who are some of Pfizer's key competitors?

Who are Pfizer's key executives?

Pfizer's management team includes the folowing people:
  • Mr. Ian C. Read, Chairman & CEO (Age 64)
  • Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)
  • Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
  • Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)
  • Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53)

Has Pfizer been receiving favorable news coverage?

News headlines about PFE stock have been trending somewhat positive on Friday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pfizer earned a news and rumor sentiment score of 0.16 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.91 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term. View Recent Headlines for Pfizer.

Who are Pfizer's major shareholders?

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.65%), Bank of New York Mellon Corp (1.14%), Massachusetts Financial Services Co. MA (1.04%), Morgan Stanley (0.91%), Dimensional Fund Advisors LP (0.91%) and Fisher Asset Management LLC (0.66%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Which institutional investors are selling Pfizer stock?

PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Russell Investments Group Ltd., Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado, Legal & General Group Plc, Advisors Asset Management Inc. and American Century Companies Inc.. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

Which institutional investors are buying Pfizer stock?

PFE stock was bought by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Dimensional Fund Advisors LP, Macquarie Group Ltd., Federated Investors Inc. PA, Jensen Investment Management Inc., Natixis, Fisher Asset Management LLC and Unigestion Holding SA. View Insider Buying and Selling for Pfizer.

How do I buy shares of Pfizer?

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfizer's stock price today?

One share of PFE stock can currently be purchased for approximately $41.42.

How big of a company is Pfizer?

Pfizer has a market capitalization of $243.65 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

How can I contact Pfizer?

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.


MarketBeat Community Rating for Pfizer (NYSE PFE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,093 (Vote Outperform)
Underperform Votes:  603 (Vote Underperform)
Total Votes:  1,696
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.